Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty

Olivia Manfrini; Carmine Pizzi; GianLuigi Morgagni; Fiorella Fontana; Raffaele Bugiardini

doi:10.1016/j.amjcard.2004.02.037

Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty

Am J Cardiol. 2004 Jun 1;93(11):1391-3, A6. doi: 10.1016/j.amjcard.2004.02.037.

Authors

Olivia Manfrini¹, Carmine Pizzi, GianLuigi Morgagni, Fiorella Fontana, Raffaele Bugiardini

Affiliation

¹ Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy.

PMID: 15165921
DOI: 10.1016/j.amjcard.2004.02.037

Abstract

We studied the effect of pravastatin on coronary perfusion after percutaneous transluminal coronary angioplasty. An exercise test performed within 2 weeks after percutaneous transluminal coronary angioplasty induced reversible perfusion defects in 66% of patients taking pravastatin and 64% of those taking placebo. At follow-up, the exercise test still induced reversible perfusion defects in 3% of patients taking pravastatin and 29% of those taking placebo.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Angioplasty, Balloon, Coronary*
Coronary Angiography
Coronary Circulation / drug effects*
Coronary Stenosis / diagnostic imaging
Coronary Stenosis / drug therapy
Coronary Stenosis / therapy*
Exercise Test
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Male
Middle Aged
Pravastatin / therapeutic use*
Prospective Studies
Single-Blind Method
Time Factors
Tomography, Emission-Computed, Single-Photon

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin